News

Interview with non-executive Director Dr Paul Wotton

This is an exclusive interview with Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016.  He was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Atellas Pharma valued at $379 million.

Interview with Paul Wotton, Current Board Member of Cynata Therapeutics and Previous President/CEO of Ocata Therapeutics